SPTBN2 Promotes the Progression of Thyroid Cancer by Accelerating G1/S Transition and Inhibiting Apoptosis

Figure 2

SPTBN2 expression in thyroid cells and siRNA transfection efficiency in KTC-1 and BCPAP. SPTBN2 knockdown inhibited TC cell line proliferation. (a) Relative expression of SPTBN2 (normalized to GADPH) in the three malignant thyroid cell lines and HTORI-3 (normal thyroid follicular epithelial cell line). (b) Relative expression of SPTBN2 (normalized to GADPH) in the TC cell lines (KTC-1 and the BCPAP) after siRNA treatment as detected via qRT-PCR. (c) SPTBN2 protein level in the thyroid cell lines HTORI-3, TPC-1, KTC-1, and BCPAP and the siRNA-transfected KTC-1 and BCPAP cell lines as determined via WB analysis. (d) Quantitative results of the (C) WB analysis (normalized to β-actin). (e) Colony formation assay. TC cells treated with siRNA were plated onto six-well plates and incubated for 7 days. Compared with that of the Si-NC group, the proliferation capacity of the malignant thyroid cell lines in the Si-RNA1 and Si-RNA2 groups was exceedingly high. (f) Relative quantification of the (E) colony formation assay. (g) CCK-8 proliferation assay was conducted to quantify the proliferation of transfected cells. The data are presented as the (three independent experiments). .

(a)

(b)

(c)

(d)

(e)

(f)

(g)